long-term effects of glp-1 medications Infographic The GLP-1 Agonists and Obesity:

2013 doi: 10.2337/db13-1440

In the recently published data for the treatment period after 52 weeks, patients treated with tirzepatide maintained A1C and weight control for up to 2 years

It affects the GLP one receptor but also the GIP receptor, which are both involved in hunger and satiety and motility. Dan Azagury, MD, FACS, the chief bariatric surgeon and medical director of Stanford University School of Medicines Lifestyle and Weight Management Clinic in California, who also was not involved in the Eli Lilly study, told Healthline that he was not surprised at the studys results

Ross, and staff

Structure Therapeutics is among the most advanced challengers, with its oral GLP-1 receptor agonist aleniglipron generating Phase 2 data that has drawn significant industry attention